Research On Premium Performance Of Listed Companies

Xiangxue pharmaceutical companies as a rapid development of emerging enterprises, raise funds through the use of large-scale mergers and acquisitions to expand their scale quickly. On May 24,2013, a fortune mergers and acquisitions in the pharmaceutical industry in Shanghai qiaocheng pharmaceutical, since this is a company listed one of the biggest mergers and acquisitions. Qiaocheng m&a Shanghai pharmaceutical industry in the development of an enterprise for rapid xiangxue pharmacy meaning is huge, and the company is also full of confidence for the m&a. So how exactly m&a performance?With one case study method, this article first to guangzhou xiangxue qiaocheng pharmaceutical pharmaceutical co., LTD. Mergers and acquisitions Shanghai case introduced; Secondly, through the financial indicators and stock price movements, the operating conditions of before and after the merger and acquisition the transverse and longitudinal comparison; Then from the Angle of the m&a targets, further analysis of merger synergies, before financial analysis on the basis of comprehensive description of m&a performance.Through the study found that in the short term, the acquisition to a certain extent weakened the xiangxue pharmaceutical company’s core competitiveness. Xiangxue pharmaceutical companies through the merger, acquisition and reorganization, the Shanghai qiaocheng pharmaceutical company many advantage resources, improve the product structure, strategic layout, enhance the company brand influence. However, the acquisition premium is high, failed to achieve expected returns after the merger, enterprise to make ends meet. And enterprise’s merger and acquisition speed problem, the stress of m&a integration. This paper hope through the high premium m&a case analysis, provide reference for the same type of mergers and acquisitions in the future.